The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kuznetsova O.A.

Russian Medical Academy of Continuous Professional Education

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

Demidova I.A.

Moscow City Oncology Hospital No. 62

Gikalo M.B.

Moscow City Oncology Hospital No. 62

Frank G.A.

Russian Medical Academy of Continuous Professional Education

Importance of detecting TRK protein expression and rearrangements in NTRK3 gene in secretory carcinoma of the breast

Authors:

Kuznetsova O.A., Andreeva Yu.Yu., Zavalishina L.E., Demidova I.A., Gikalo M.B., Frank G.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2020;82(4): 53‑57

DOI: 10.17116/patol20208204153

Read: 2974 times

Download PDF (RU)
Contact the author
Table of contents

IMPORTANCE OF DETECTING TRK PROTEIN EXPRESSION AND REARRANGEMENTS IN NTRK3 GENE IN SECRETORY CARCINOMA OF THE BREAST
IMPORTANCE OF DETECTING TRK PROTEIN EXPRESSION AND REARRANGEMENTS IN NTRK3 GENE IN SECRETORY CARCINOMA OF THE BREAST

To cite this article:

Kuznetsova OA, Andreeva YuYu, Zavalishina LE, Demidova IA, Gikalo MB, Frank GA. Importance of detecting TRK protein expression and rearrangements in NTRK3 gene in secretory carcinoma of the breast. Russian Journal of Archive of Pathology. 2020;82(4):53‑57. (In Russ.)
https://doi.org/10.17116/patol20208204153

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Secretory carcinoma of the breast is a rare malignant tumor with a relatively favorable prognosis and indolent course. Despite this, it can lead to death or reduce the quality of life. Advances in modern chemotherapy, such as tyrosine kinase inhibitors, can not only extend life, but also reduce the volume of surgery. However, this therapy is not applicable for every patient, but only for those with translocation of the NTRK3 gene.

Keywords:

secretory carcinoma of the brest
NTRK

Authors:

Kuznetsova O.A.

Russian Medical Academy of Continuous Professional Education

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

Demidova I.A.

Moscow City Oncology Hospital No. 62

Gikalo M.B.

Moscow City Oncology Hospital No. 62

Frank G.A.

Russian Medical Academy of Continuous Professional Education

Received:

25.03.2020

Accepted:

20.04.2020

Close metadata

References:

  1. Li D, Xiao X, Yang W, Shui R, Tu X, Lu H, Shiet D. Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. Mod Pathol. 2012;25(4):567-575.  https://doi.org/10.1038/modpathol.2011.190
  2. Mun SH, Ko EY, Han BK, Shin JH, Kim SJ, Cho EY. Secretory carcinoma of the breast: sonographic features. J Ultrasound Med. 2008;27(6):947-954.  https://doi.org/10.7863/jum.2008.27.6.947
  3. WHO Classification of Tumours series. vol. 2. Breast Tumours. 5th ed. IARC; 2019.
  4. Horowitz DP, Sharma CS, Connolly E, Gidea-Addeo D, Deutsch I. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast. 2012;21(3):350-353.  https://doi.org/10.1016/j.breast.2012.02.013
  5. Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551. https://doi.org/10.1097/PAS.0000000000000911
  6. Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58-66.  https://doi.org/10.1016/j.pharmthera.2017.02.006
  7. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023. https://doi.org/10.1136/esmoopen-2015-000023
  8. Davis JL, Lockwood CM, Albert CM, Tsuchiya K, Hawkins DS, Rudzinski ER. Infantile NTRK-associated mesenchymal tumors. Pediatr Dev Pathol. 2018;21(1):68-78.  https://doi.org/10.1177/1093526617712639
  9. Pavlick D, Schrock AB, Malicki D, Stephens PJ, Kuo DJ, Ahn H, Turpin B, Allen JM, Rosenzweig M, Badizadegan K, Ross JS, Miller VA, Wong V, Ali SM. Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer. 2017;64(8):e26433. https://doi.org/10.1002/pbc.26433
  10. Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov Y. E.NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016;122(7):1097-1107. https://doi.org/10.1002/cncr.29887
  11. Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32(1):147-153.  https://doi.org/10.1038/s41379-018-0118-3
  12. Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016;469(5):489-503.  https://doi.org/10.1007/s00428-016-2000-3
  13. Church AJ, Calicchio ML, Nardi V, Skalova A, Pinto A, Dillon DA, Gomez-Fernandez CR, Manoj N, Haimes JD, Stahl JA, Dela Cruz FS, Tannenbaum-Dvir S, Glade-Bender JL, Kung AL, DuBois SG, et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018;31(3):463-473.  https://doi.org/10.1038/modpathol.2017.127
  14. Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24(7):937-946.  https://doi.org/10.1097/00000478-200007000-00005
  15. Demetri GD, Paz-Ares L, Farago AF, Liu SV, Chawla SP, Tosi D, Kim ES, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Ann Oncol. 2018;29(suppl 9):175.  https://doi.org/10.1093/annonc/mdy483.003
  16. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739.  https://doi.org/10.1056/NEJMoa1714448
  17. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis. Oncol. 2018. https://doi.org/10.1200/PO.18.00183
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.